{
  "docId": "019de076-87a3-715f-b988-6da9cfb3fd56",
  "docSlug": "560176b410a72a6b2e67af5dd2a20758",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 33,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "The slide highlights clinical trial safety data for PrimeC.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/16",
  "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56",
  "deckJsonHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56.json",
  "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.17,
        "w": 0.34,
        "x": 0.13,
        "y": 0.71
      },
      "kind": "callout",
      "text": "All Adverse Events Were Transient and Expected",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fdaf7ed-071b-46f5-bf4b-a62095743f5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.17,
        "w": 0.34,
        "x": 0.49,
        "y": 0.71
      },
      "kind": "callout",
      "text": "No Drop-outs Due To Adverse Events",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2324b9c-32c1-4d34-a849-d2172a3c2438",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.13,
        "x": 0.85,
        "y": 0.02
      },
      "kind": "image",
      "text": "NeuroSense Therapeutics",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f4e3fa4-6eec-4a11-b7b1-92f6fc81fcbb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.69,
        "x": 0.13,
        "y": 0.305
      },
      "kind": "table",
      "text": "Summary of All Adverse Events; PrimeC (N=45); Placebo (N=23); Adverse Events (AE) 68.9% 65.2%; Treatment-Emergent AEs (TEAE) 68.9% 65.2%; Study Drug Related TEAE 20.0% 4.3%; Serious TEAE 8.9% 8.6%; Subject death 4.4% 4.3%; TEAE leading to Discontinuation 6.7% 4.3%; TEAE leading to Reduction 0.0% 0.0%; TEAE leading to Interruption 15.6% 8.6%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78a70437-7cf4-4e3f-9097-43fb1b4625e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.75,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "PrimeC Phase 2b Study Results\nAchieved Primary Endpoints with a Safety\nand Tolerability Profile Comparable to Placebo",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e17e6a25-56b4-4c3e-b07e-ec6cb620eafa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 6,
      "beatId": "34d973c9-414c-4e7d-9b2b-216172775550",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 17,
      "from": 16,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "eac28707-c928-4f11-b43c-15fe53094ee6",
      "evidence": "The document presents data showing that PrimeC significantly attenuated disease progression by 37% in ALSFRS-R.",
      "position": 1,
      "objective": "How does PrimeC compare to placebo in terms of disease progression?",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}